<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04251364</url>
  </required_header>
  <id_info>
    <org_study_id>Expedition5300</org_study_id>
    <nct_id>NCT04251364</nct_id>
  </id_info>
  <brief_title>Treatment of Chronic Mountain Sickness</brief_title>
  <acronym>Exp5300</acronym>
  <official_title>Acetazolamide and Statins for the Treatment of Chronic Mountain Sickness in Highlanders: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d'Expertise sur l'Altitude EXALT</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre d'Expertise sur l'Altitude EXALT</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the effect of two drugs for the treatment of chronic mountain&#xD;
      sickness in highlanders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 100 million individuals reside at high altitude (&gt;2500m) worldwide, with the largest&#xD;
      populations of highlanders being found in South America (Andean), central Asia (Tibetan and&#xD;
      Sherpa) and East Africa (Ethiopian). Despite unique adaptations to hypoxia in these&#xD;
      populations, chronic mountain sickness (CMS) is a clinical syndrome which is observed in&#xD;
      5-33% of individuals residing permanently at high altitude.Several pharmacological approaches&#xD;
      have been proposed in the treatment of EE and CMS. However, few studies show sufficient&#xD;
      clinical evidence for safety and efficacy in CMS treatment and most highlanders with CMS&#xD;
      remain untreated. The present project aims to better characterize chronic hypoxic responses&#xD;
      in highlanders and to evaluate the interest of acetazolamide and statins as potential&#xD;
      treatments for chronic mountain sickness.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hematocrit</measure>
    <time_frame>Change from before to after 9 months of treatment</time_frame>
    <description>Change in blood hematocrit value in percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic mountain sickness score</measure>
    <time_frame>Change from before to after 9 months of treatment</time_frame>
    <description>Chronic mountain sickness score (between 0 and 24, the higher the score the more severe the sickness) according to the available international scoring system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrovascular reactivity</measure>
    <time_frame>Change from before to after 9 months of treatment</time_frame>
    <description>Post-ischemia brachial artery dilation in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular reactivity</measure>
    <time_frame>Change from before to after 9 months of treatment</time_frame>
    <description>Hyperthermic microvascular dilation in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin mass</measure>
    <time_frame>Change from before to after 9 months of treatment</time_frame>
    <description>Total blood hemoglobin mass in mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary arterial pressure</measure>
    <time_frame>Change from before to after 9 months of treatment</time_frame>
    <description>Systolic and mean pulmonary arterial pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Change from before to after 9 months of treatment</time_frame>
    <description>24-hour systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep recording</measure>
    <time_frame>Change from before to after 9 months of treatment</time_frame>
    <description>Hypopnea-apnea index reported in number of events per hour</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hypoxia, Altitude</condition>
  <arm_group>
    <arm_group_label>Acetazolamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral acetazolamide (250 mg/day) intake for 9 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral atorvastatin (40 mg/day) intake for 9 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo pill (daily) intake for 9 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetazolamide</intervention_name>
    <description>Daily acetazolamide pill intake</description>
    <arm_group_label>Acetazolamide</arm_group_label>
    <other_name>Diamox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Daily atorvastatin pill intake</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Daily placebo pill intake</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male&#xD;
&#xD;
          -  Age between 18 and 55 yrs&#xD;
&#xD;
          -  Body mass index &lt;30kg/m²&#xD;
&#xD;
          -  Born at &gt;3500 m, living for &gt;3 years at the local high altitude&#xD;
&#xD;
          -  No diagnosis of cardiorespiratory, metabolic or neurological diseases&#xD;
&#xD;
          -  No drug intake&#xD;
&#xD;
          -  No smoker&#xD;
&#xD;
          -  Chronic mountain sickness score ≥6&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of cardiorespiratory, metabolic and neurological diseases&#xD;
&#xD;
          -  Systolic &gt; 130 mmHg and/or diastolic &gt; 85 mmHg blood pressure&#xD;
&#xD;
          -  Drug intake&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
          -  Chronic mountain sickness score &lt;6&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Verges, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>EXAL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samuel Verges, PhD</last_name>
    <phone>0476766860</phone>
    <phone_ext>33</phone_ext>
    <email>sverges@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Association EXALT, UM Sport Pathologies, Hôpital Sud, Avenue Kimberley</name>
      <address>
        <city>Échirolles</city>
        <zip>38130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Verges, PhD</last_name>
      <phone>476766860</phone>
      <phone_ext>33</phone_ext>
      <email>sverges@chu-grenoble.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2020</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Altitude Sickness</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetazolamide</mesh_term>
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

